TAHO PHARMACEUTICALS LTD.

Area: Pharmaceutical and Medical Devices

Booth No: M312

Exhibitor Profile

Founded in 2010, TAHO pioneers innovative dosage forms like transdermal patches and oral dissolving films (ODFs) using its Transepithelial Delivery System. Its Ondansetron ODF is marketed in Japan, and TAH9922 for ADHD is licensed for U.S. market. TAHO’s pipeline targets CNS disorders, including Alzheimer’s, pediatric ADHD, epilepsy, and opioid addiction, with a novel anticoagulant ODF ready for FDA/EMA NDA filing. TAHO also drives collaborative projects with its robust research capabilities.